Alprostadil detailed information

Alprostadil detailed information

Clinical data
ATC code	C01EA01 (WHO) G04BE01 (WHO)
Identifiers
IUPAC name 7-[3-hydroxy-2-(3-hydroxyoct-1-enyl)- 5-oxo-cyclopentyl] heptanoic acid
CAS Number	745-65-3
PubChem CID	149351
DrugBank	APRD00785
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H34O5
Molar mass	354.481 g/mol

WikiDoc Resources for Alprostadil detailed information
Articles
Most recent articles on Alprostadil detailed information Most cited articles on Alprostadil detailed information Review articles on Alprostadil detailed information Articles on Alprostadil detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Alprostadil detailed information Images of Alprostadil detailed information Photos of Alprostadil detailed information Podcasts & MP3s on Alprostadil detailed information Videos on Alprostadil detailed information
Evidence Based Medicine
Cochrane Collaboration on Alprostadil detailed information Bandolier on Alprostadil detailed information TRIP on Alprostadil detailed information
Clinical Trials
Ongoing Trials on Alprostadil detailed information at Clinical Trials.gov Trial results on Alprostadil detailed information Clinical Trials on Alprostadil detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Alprostadil detailed information NICE Guidance on Alprostadil detailed information NHS PRODIGY Guidance FDA on Alprostadil detailed information CDC on Alprostadil detailed information
Books
Books on Alprostadil detailed information
News
Alprostadil detailed information in the news Be alerted to news on Alprostadil detailed information News trends on Alprostadil detailed information
Commentary
Blogs on Alprostadil detailed information
Definitions
Definitions of Alprostadil detailed information
Patient Resources / Community
Patient resources on Alprostadil detailed information Discussion groups on Alprostadil detailed information Patient Handouts on Alprostadil detailed information Directions to Hospitals Treating Alprostadil detailed information Risk calculators and risk factors for Alprostadil detailed information
Healthcare Provider Resources
Symptoms of Alprostadil detailed information Causes & Risk Factors for Alprostadil detailed information Diagnostic studies for Alprostadil detailed information Treatment of Alprostadil detailed information
Continuing Medical Education (CME)
CME Programs on Alprostadil detailed information
International
Alprostadil detailed information en Espanol Alprostadil detailed information en Francais
Business
Alprostadil detailed information in the Marketplace Patents on Alprostadil detailed information
Experimental / Informatics
List of terms related to Alprostadil detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Alprostadil is the pharmaceutical name for prostaglandin E₁. It is used as a drug in the treatment of erectile dysfunction and has vasodilatory properties.

Sexual dysfunction

Aprostidil is sold in the United States under the brand name Muse. It is also sold as Caverject and Edex.

Muse delivers alprostadil as a penile suppository, inserted into the urethra, at least ten minutes before the erection will be needed. Caverject and Edex are similarly fast-acting, but are actually injected directly into the corpus cavernosum of the penis.

This drug is reputed to work for erectile dysfunction for 30 to 60 minutes.

This drug, following on the coattails of Viagra, has failed to achieve comparable above-ground market share in the United States, perhaps in part because of the invasive means of delivery.

NexMed is developing transdermal forumulations—Alprox-TD(R) for men with erectile dysfunction and Femprox(R) for female sexual arousal disorder. Alprox-TD(R) has been selling in China and in Hong Kong since October 2001 and April 2002, respectively. Two Phase III studies have been completed for this product, and the Company is seeking regulatory approval in the U.S., Canada and Europe.

Other uses

Aprostadil is also used in maintaining a patent ductus arteriosus in the fetus. This is primarily useful when there is threat of premature closure of the ductus arteriosus.

References

Template:WikiDoc Sources